Palifermin, (Kepivance), recombinant human keratinocyte growth factor, has been approved for treatment of patients with mucositis after high-dose chemotherapy followed by auto-SCT and/or irradiation.
The registered dose of palifermin is fixed at 60 mg/kg for 3 days before (myeloablative) therapy and for 3 days after therapy. Spielberger et al. 1 showed that this treatment schedule reduced grade 3-4 mucositis, decreased the use of opioid analgesics and total parenteral nutrition in patients treated with high-dose chemoradiotherapy and auto-SCT. We report a single center study designed to validate the mucositis scoring system in our hospital, which sheds an unexpected light on the effect and dosing of palifermin.
We studied 10 patients treated for multiple myeloma with high-dose melphalan (200 mg/m 2 in two consecutive days) followed by auto-SCT. Five patients received ice to chew on during melphalan infusion and five patients received palifermin in the aforementioned dose if feasible. They were not randomly allocated. In each group, sequential assessments of the mucositis were performed by five observers at five time points, using the WHO mucositis scoring system. Also, pH of saliva, taste (different tests for sweet, sour, salt, bitter), use of analgesics and ability to swallow food were monitored.
The scoring system was validated using calculation of the weighted k value, that was 0.72, categorized as 'excellent' by Fleiss. 2 All five patients receiving palifermin developed a skin rash after three dosages. Three out of five patients needed morphine (opposed to none in the non-palifermin group) and all needed adjustment of their diet to fluids only, whereas three patients in the non-palifermin group were able to continue their standard diet.
Moreover, in three of five patients we needed to interrupt the treatment with palifermin after three doses and in one patient after four doses, because of severe swelling of the oral mucosa and neck region. The most striking difference was the development of mucositis. Four patients who received palifermin developed mucositis (WHO grade 3-4), and only one patient who did not receive palifermin developed mucositis (WHO grade 3). The mucosal changes induced by palifermin may resemble mucositis, increasing the thickness of the mucosa instead of harming it, but in addition to color changes, ulceration and diarrhea were also seen.
One patient who received palifermin had a significant decrease in taste; all other patients had no change in taste. No significant differences in saliva pH were observed in the two groups. See Table 1 for an overview of the results.
In this small number of patients, it seems that in patients treated with high-dose melphalan and auto-SCT, treatment with palifermin was associated with greater use of opioid analgesics and less oral intake without a beneficial effect on mucositis. Moreover, palifermin had to be stopped prematurely because of side effects on the skin and facial swelling in three out of five patients, suggesting overdosage. The original dosing of palifermin was designed for a specific intensive chemoradiotherapeutic regimen. 1 In the high-dose melphalan scheme, the interval between the doses of palifermin is shorter than in the registration study. This most likely creates a cumulative effect that may necessitate discontinuation of palifermin. We suggest that palifermin dose should not be fixed. A study in cooperation with the EBMT is now being performed addressing this issue, specifically in patients treated with high-dose melphalan. 3 More studies such as this are needed to adopt the dose to other chemotherapeutic and/or radiotherapeutic regimens. The Netherlands E-mail: m.wondergem@vumc.nl Table 1 Results 
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